<DOC>
	<DOC>NCT00087594</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous intravenous (iv) drug users who have CHC and are currently enrolled in a methadone maintenance treatment program. The anticipated time on study treatment is 1-2 years, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>adult patients at least 18 years of age CHC infection, genotype 1, 2, or 3 naive to treatment for CHC infection enrolled in a methadone maintenance program with documented attendance for at least 3 months use of 2 forms of contraception during the study on both men and women previous treatment for CHC infection coinfection with human immunodeficiency virus (HIV) current use of IV or other illicit drugs decompensated cirrhosis women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>